Zobrazeno 1 - 10
of 86
pro vyhledávání: '"D. Aguiar Bujanda"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
R. Ten Benajes, S. Saura Grau, S. Galvan Ruiz, R. Martinez Garcia-Cervantes, C. Antonilli Perez, G. Rubio Romero, M. Hernandez Sosa, A.M. Vargas Prado, D. Perez Cabrera, B. Fox, D. Aguiar Bujanda, M. Mori De Santiago, L. Ros Sanjuan, L. Croissier Sanchez, R. Hanselmann
Publikováno v:
Annals of Oncology. 32:S51-S52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8146a5667fbb0a6fca788136e9f3258
https://doi.org/10.1016/j.annonc.2021.03.085
https://doi.org/10.1016/j.annonc.2021.03.085
Autor:
M.-R. García-Campelo, C. Camps Herrero, D. Aguiar Bujanda, E. Carcereny Costa, J.M. Oramas Rodriguez, E. del Barco Morillo, J. Bosch Barrera, D. Rodriguez Abreu, M. Guirado, A. Padilla, R. Bernabé, M. Domine Gomez, Jose-Luis Gonzalez-Larriba, A.L. Ortega Granados, M. Provencio, R. Blanco Guerrero, Julio Casal, R. Lopez Castro, M.A. Sala, B. Massuti Sureda
Publikováno v:
Annals of Oncology. 30:v749
Background Target therapy guide by biomarkers have become the standard of care for patients with lung cancer (LC). So, identify those molecular alterations is one of the most important care needs nowdays. Our objective was to know the implementation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eec711469aacbc7799222b21eac198a
https://doi.org/10.1093/annonc/mdz266.005
https://doi.org/10.1093/annonc/mdz266.005
Autor:
M. Guirado, S. Cerezo Gonzalez, J.M. Oramas Rodriguez, C. Camps Herrero, R. Lopez Castro, M.-R. García-Campelo, E. Carcereny Costa, E. del Barco Morillo, B. Massuti Sureda, D. Rodriguez Abreu, M. Provencio, Alejandro Padilla, D. Aguiar Bujanda, Jose-Luis Gonzalez-Larriba, M. Domine Gomez, R. Bernabé, M.A. Sala, A.L. Ortega Granados, N. De Dios Alvare, J. Bosch Barrera
Publikováno v:
Annals of Oncology. 30:v749
Background Tobacco use, mainly as cigarette smoking, is the leading cause of lung cancer. Eighty-five percent of LC occur in smokers. Understanding the Spanish smoking habits allows the government to design health care policies against this consumpti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc87bd68cdb7dfa7dc1e231d5665986f
https://doi.org/10.1093/annonc/mdz266.004
https://doi.org/10.1093/annonc/mdz266.004
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
L. de la Cruz Merino, A. Lopez-gonzalez, M. Mendez Garcia, C. Quero Blanco, F.R. Garcia Arroyo, M.A. Cruz Mora, Javier Lavernia, V. Calvo De Juan, Delvys Rodriguez-Abreu, Pilar Sabin, J. Gomez Codina, F. Franco Perez, Marta Llanos, A. Rueda, D. Aguiar Bujanda, Josep Gumá, M. Provencio, J.J. Sabchez, Natividad Martínez
Publikováno v:
European Journal of Cancer. 51:S652-S653
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c08376c3cbf25d972a6158cd5ce50ad
https://doi.org/10.1016/s0959-8049(16)31788-9
https://doi.org/10.1016/s0959-8049(16)31788-9
Autor:
M. Provencio Pulla, D. Aguiar Bujanda, Natividad Martínez, C. Murias Enriquez, V. Calvo De Juan, F. Franco Perez, A. Lopez-gonzalez, F.R. Garcia Arroyo, M.A. Cruz Mora, L. de la Cruz Merino, Josep Gumá, Pilar Sabin, José Jurado Sánchez, Marta Llanos, A. Rueda, Delvys Rodriguez-Abreu, Javier Lavernia, C. Quero Blanco, J. Gomez Codina
Publikováno v:
European Journal of Cancer. 51:S649
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dfcf17cd341445af5d71b6294f05f1b
https://doi.org/10.1016/s0959-8049(16)31778-6
https://doi.org/10.1016/s0959-8049(16)31778-6
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 18(3)
Bisphosphonates (BP) decrease the incidence of skeletal related events among cancer patients with bone metastases from solid tumors and multiple myeloma. Renal safety and osteonecrosis of the jaws (ONJ) are two major concerns of toxicity. Information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41a4cee1f5ac0f660e318f9e6582ed4b
https://pubmed.ncbi.nlm.nih.gov/17082512
https://pubmed.ncbi.nlm.nih.gov/17082512
Autor:
Gloria González, María Victoria Cuevas, Marta Callejas, Beatriz Cuevas, Aurelio López, Albert Altés, Blanca Sanchez-Gonzalez, D. Aguiar Bujanda, Javier Munarriz, Antonio Salar, A. De la Fuente, I. García Carbonero, Carlos Grande, J.A. García Marco, Marina Morán, J. García Frade, R. Aporta, A. Murias, J. Briones Meijide, Abelardo Bárez
Publikováno v:
Annals of Oncology. 25:iv334
Aim: Temsirolimus (TEM) is an mTOR inhibitor approved for the treatment of patients (pts) with relapsed or refractory mantle cell lymphoma (MCL). In a phase III trial TEM 175mg weekly for 3 weeks followed by 75mg weekly significantly improved progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::119d96649592311fc8b69f7f98a4d332
https://doi.org/10.1093/annonc/mdu339.25
https://doi.org/10.1093/annonc/mdu339.25
Autor:
D. Aguiar Bujanda
Publikováno v:
Annals of Oncology. 19:396-397
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bea803b41ef1c79cd59caff2b4420ed
https://doi.org/10.1093/annonc/mdm579
https://doi.org/10.1093/annonc/mdm579